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Supplements are the cause of much debate in the world 
of journal publishing. Supplements are criticized for the 
fact that often they are funded by an external source, and 
journals have been known to shy away from their 
publication [1]. But is refusing to publish supplements 
the only answer? At Arthritis Research & Th  erapy, we feel 
that – if subjected to the full rigors of peer review – 
supplements can provide invaluable educational resources, 
exploring themes in a detailed and focused way that 
might not always be possible in the main journal.
At Arthritis Research & Th  erapy, we have decided that 
the potential risk of a loss of objectivity in industry-
sponsored supplements can be managed by scrupulous 
attention to the peer-review process. Th  erefore, in our 
experience, the beneﬁ  t of publishing supplements greatly 
outweighs any perception of loss of objectivity. We 
should note that our colleagues in the pharmaceutical 
industry have embraced our approach with no eﬀ  orts to 
circumvent our rules, as far as we know.
We consider proceedings, review collections, and 
meeting abstracts for inclusion as supplements. Examples 
of recent supplements are easily accessed on the journal 
website. It will be apparent that the emphasis is on the 
molecular and cellular basis of immune and inﬂ  ammatory 
mechanisms of disease. Th   e underwriting by the sponsor 
of the cost of peer review and production ensures that 
the high-quality publication is freely available. Outlined 
below is the procedure that we follow when considering 
any potential supplements for the journal. We recognize 
the potential for competing interests to inﬂ  uence  the 
content of articles where there is industry involvement, 
but we believe that by adhering to a stringent publication 
process we negate this risk with our supplement content.
So, what is the procedure? First, in a change from the 
approach taken by many journals, we appoint an ‘internal’ 
Supplement Editor (usually from the journal’s Editorial 
Board), whose role is to select peer reviewers and assess 
the suitability of the supplement articles for publication 
in the journal. Th  is internal editor is selected by the 
Editors-in-Chief, and the sponsor’s approval is not sought 
in making this appointment. Before their appointment, 
internal editors are asked to declare any potential 
conﬂ  icts of interest, and full disclosures are included in 
both online and print versions of any supplements. In 
cases in which internal editors receive a stipend, this is 
paid for by the publisher – not the sponsor. All conﬂ  ict of 
interest disclosures associated with supplement publica-
tions follow the National Library of Medicine policy for 
indexing supplement articles in MEDLINE [2].
For some supplements, particularly where articles are 
commissioned externally, there may be an ‘external’ 
Supplement Editor as well as the internal editor. Before 
their appointment, external supplement editors must be 
approved by the Editors-in-Chief. Th   eir role is to identify 
the subject matter and propose suitable authors for the 
individual supplement articles, with the proviso that all 
content must be approved by the Editors-in-Chief. Th  e 
external editor is not involved in the peer review of any of 
the articles once submitted. Th   ey are also asked for full 
conﬂ  ict of interest disclosures, which are included in the 
supplement publication alongside those of the internal 
editor.
One of the common criticisms levied against supple-
ments is that the articles are not peer-reviewed to the 
journal’s normal standards. At Arthritis Research & 
Th  erapy, supplement articles go through the same 
thorough peer-review process as articles do in the main 
journal [3]. Th   e Editors-in-Chief have full editorial control, 
including the ability to ask authors to make extensive 
revisions, and reserve the right to reject articles that do 
not meet the journal’s standards. And in accordance with 
the guidelines of the International Committee for 
Medical Journal Editors [4], all contracts clearly include 
information about editorial control and the role of the 
internal supplement editor.
In addition to disclosures from the individual editors, 
sources of funding for a supplement are prominently 
displayed on the supplement title page, and funding is 
also acknowledged in each individual article. We ensure 
that supplements can be clearly distinguished as separate  © 2010 BioMed Central Ltd
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© 2010 BioMed Central Ltdfrom the main journal content on the journal homepage. 
As with all of our articles, individual authors declare their 
conﬂ   icts of interest. Th   is complies with the good 
publication practice (GPP2) guidelines [5]. We also 
adhere to the guidelines of the European Medical Writers 
Association [6] by ensuring that the involvement of any 
medical writers is disclosed in an article’s acknowledg-
ments section along with their sources of funding.
We hope that by ensuring that there is full transparency 
of disclosures from everyone involved in supplements 
and following strictly the peer-review procedure 
described above, we avoid the potential pitfalls of supple-
ment publishing. Th  e guidelines of the International 
Committee of Medical Journal Editors themselves state 
that supplements ‘serve useful purposes’ and it is our 
responsibility as editors to ensure that they continue to 
be useful without allowing ourselves to be subject to 
industry inﬂ  uence. By publicly disclosing our policy for 
supplement review here, we hope that other journals will 
be more open about their peer-review policies for 
supplements and that they adopt similarly stringent 
practices in the future.
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